A phase II, open-label study, Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia (NCT05509595), is currently ongoing for adult and pediatric patients.38 Here, FGF23 is linked to hypophosphatemia.